<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006057</url>
  </required_header>
  <id_info>
    <org_study_id>199/15151</org_study_id>
    <secondary_id>MTS-GCO-88-459</secondary_id>
    <nct_id>NCT00006057</nct_id>
  </id_info>
  <brief_title>Diagnostic and Screening Study of Genetic Disorders</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Center for Research Resources (NCRR)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the phenotypic heterogeneity of patients with genetic disorders&#xD;
      including their clinical spectrum and natural history.&#xD;
&#xD;
      II. Develop and evaluate novel methods for the treatment of genetic disorders including&#xD;
      metabolic manipulation, enzyme manipulation, enzyme replacement, enzyme transplantation, and&#xD;
      gene transfer techniques in these patients.&#xD;
&#xD;
      III. Develop and evaluate methods for the prenatal diagnosis of genetic disorders using&#xD;
      improved cytogenetic, biochemical, and nucleic acid techniques and amniotic fluid cells or&#xD;
      chorionic villi in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE:&#xD;
&#xD;
      Patients are evaluated annually or biannually, depending on disease status and progression.&#xD;
      Patients undergo a complete medical history, an extensive family pedigree, and a physical&#xD;
      examination. Patients undergo general laboratory, imaging, physiologic, and clinical&#xD;
      laboratory studies according to their disease type. Patients undergo specialized laboratory&#xD;
      studies including plasma and leukocyte enzyme assays, quantitative urinary&#xD;
      mucopolysaccharides and oligosaccharides, urine and plasma glycolipids, plasma and urine&#xD;
      amino acids, urine organic acids, lymphoblastoid culture, DNA isolation from peripheral&#xD;
      leukocytes, skin biopsy for fibroblast culture (if indicated), and medical photography.&#xD;
      Patients also receive consultations with various specialties including ophthalmology, ENT,&#xD;
      cardiology, pulmonary, gastroenterology/nutrition, hematology, neurology, orthopedics,&#xD;
      rehabilitation medicine/physical therapy, and dermatology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1999</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>50</enrollment>
  <condition>Tay-Sachs Disease</condition>
  <condition>Porphyria, Erythropoietic</condition>
  <condition>Leukodystrophy, Globoid Cell</condition>
  <condition>Metabolism, Inborn Errors</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  Suspected diagnosis (homozygous or heterozygous) of a genetic disorder including, but&#xD;
             not limited to, one of the following: Tay-Sachs disease (adult form) Congenital&#xD;
             erythropoietic porphyria Galactosemia Mitochondrial myopathy Globoid cell&#xD;
             leukodystrophy (Krabbe disease) Methylmalonic acidemia Isovaleric acidemia Morquio&#xD;
             type A Glycogen storage disease type 1AB Ornithine aminotransferase deficiency Ceroid&#xD;
             lipofuscinosis Glutaric aciduria type 1 Citrullinemia Other malformation syndromes,&#xD;
             lysosomal storage disorders, or peroxisomal disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith P. Willner</last_name>
    <role>Study Chair</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2002</verification_date>
  <study_first_submitted>July 5, 2000</study_first_submitted>
  <study_first_submitted_qc>July 5, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2000</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tay-Sachs Disease</mesh_term>
    <mesh_term>Leukodystrophy, Globoid Cell</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Porphyrias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

